Smith holds a PhD in Biochemistry from the University of Wisconsin–Madison and a BS in Biochemistry from the University of Nebraska–Lincoln. He also operates Smith Biotech Consulting LLC, through ...

Deciphera Pharmaceuticals’ DCPH shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a definitive merger agreement with ...

"We've gotten to stage 1 and 2 on a global level, but in order to start recording sales at a quicker pace, we need to obtain a pipeline from outside. This acquisition is the first step in that ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

Ono Pharmaceutical has agreed to acquire Deciphera Pharmaceuticals for $2.4 billion, the companies said today, in a deal designed to grow the buyer’s oncology portfolio with an approved therapy, a ...

Deciphera also brings ripretinib, marketed under the brand name Qinlock, to the deal. Credits: ESB Professional/Shutterstock.com Deciphera Pharmaceuticals is set to ...

Deciphera Pharmaceuticals, a Waltham cancer biotech, said Monday it will be bought by Ono Pharmaceutical for $2.4 billon to expand the Japanese firm’s oncology portfolio and spur its growth in the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Deciphera Pharmaceuticals' stock has rallied 50% since October after positive trial data for its drug vimseltinib in the treatment of TGCT. Vimseltinib has the potential to make significant progress ...

Deciphera Pharmaceuticals Inc DCPH announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT) not amenable to surgery. The study met ...

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...